Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

Chinese drugmakers snag antibody expert Ambrx in joint buyout

May 22, 2015
Life sciences
A group of Chinese biotech heavyweights are banding together to buy Ambrx, R&D partner to the likes of Bristol-Myers Squibb and Merck, in hopes of making the company a go-to collaborator in their native country.
 
Under the deal, drugmaker Fosun Pharma, CRO WuXi PharmaTech and investors China Everbright and HOPU Investments have joined forces to acquire Ambrx, which is headquartered in San Diego. The consortium isn’t disclosing a price tag, saying only that it plans to close the deal next quarter.
 
Ambrx has made its name crafting so-called antibody-drug conjugates (ADCs), in which researchers pair toxic chemicals with targeted antibodies to treatments that can home in on tumors while sparing surrounding tissues. Beyond its stable of R&D partners, the biotech has a proprietary pipeline of ADC treatments led by ARX788, a breast cancer treatment slated to enter the clinic this year.
 
Ambrx’s collaborators–a group that also includes Astellas, Eli Lilly and Zhejiang Hisun Pharmaceutical–have paid the biotech more than $200 million in upfront cash and milestone payments, and the company’s soon-to-be owners believe they can raise its profile in China’s growing market for biotech R&D.
 
“Upon completion of the acquisition, Ambrx will obtain quality resources from its Chinese partners, so as to further advance the technical innovation of their research center based in the U.S., and to establish a global product development center based in China,” China Everbright CEO Chen Shuang said in a statement.
 
Ambrx, a 2005 Fierce 15 honoree, swung for an $86 million IPO amid 2014’s deluge of Wall Street debuts but later scuttled those plans and had largely remained quiet ever since.
 
By Damian Garde
 

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

Read more
April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

Read more
April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

Read more
More news

How can we help you?

We're easy to reach